- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
- The Hot Pink Party
You are here
PRESS RELEASE: The Breast Cancer Research Foundation Announces the Continued Expansion of the Drug Research Collaborative to Speed the Delivery of New Treatment Options
NEW YORK, NY – December 11, 2019 – The Breast Cancer Research Foundation (BCRF) announced $5 million in funding provided by Eli Lilly and Company to conduct investigator-initiated studies of the CDK4 & 6 inhibitor, Verzenio® (abemaciclib).
An upcoming clinical trial will evaluate the use of contrast enhanced mammography as a breast cancer screening option for women with dense breast tissue
Raise money for lifesaving research this holiday season and throughout the new year.
Recorded Live from New York City
BCRF attended the fifth annual Conquer Cancer Scientific and Career Development Retreat designed to empower early career researchers.
Learn how you can become a Team BCRF runner in this year’s 13.1-mile race
Carol Chaoui who is living with metastatic breast cancer, will participate in the race with her daughter, Lina.
The inspiration of a BCRF metastasis researcher, recaps from signature events, ASCO 2019 science updates and more
BCRF Corporate Partners offer simple ways to give back this month and beyond.
The Editor-in-Chief of ELLE magazine will host BCRF's upcoming Symposium & Awards Luncheon
Stay Up To Date
Don’t miss out. Let us update you when we post stories you care about.